Ainos, Inc. announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial. This trial will evaluate VELDONA, Ainos' low-dose oral interferon formulation, as a potential treatment for oral warts in HIV-positive patients. VELDONA has previously received Orphan Drug Designation from the U.S. Food and Drug Administration for this indication.
The next step for the company involves securing approval from the Taiwan Food and Drug Administration (TFDA) to proceed with the study. This IRB approval marks a critical regulatory milestone, advancing VELDONA's development for an underserved patient population. The trial aims to assess the efficacy and safety of VELDONA in this specific patient group.
This progress is vital for Ainos' human health pipeline, particularly for an orphan drug indication. The company's ability to secure such approvals demonstrates its commitment to bringing innovative therapies to patients. It also highlights the ongoing development of its VELDONA platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.